Enliven Therapeutics (ELVN) Preferred Shares (2022)

Enliven Therapeutics' (ELVN) quarterly Preferred Shares came in at $149.7 million in Q4 2022.

Enliven Therapeutics (ELVN) Preferred Shares (2022) Analysis & Trends

Enliven Therapeutics has disclosed Preferred Shares across 1 years of filings, most recently posting $149.7 million for Q4 2022.

Preferred Shares for Q4 2022 came in at $149.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $149.7 million (changed N/A YoY), and the FY2022 annual result was $149.7 million, changed N/A from the prior year.
Preferred Shares came in at $149.7 million for Q4 2022 at Enliven Therapeutics.
In the past five years, Preferred Shares ranged from a high of $149.7 million in Q4 2022 to a low of $149.7 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Enliven Therapeutics	2.32 Bn	2.32 Bn	-	-

Download Data

Date	Value
Dec 31, 2022	149.75 Mn